Boule Diagnostics Valuation
Is BOULS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BOULS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BOULS (SEK26.3) is trading below our estimate of fair value (SEK98.5)
Significantly Below Fair Value: BOULS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BOULS?
Key metric: As BOULS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BOULS's PE Ratio? | |
|---|---|
| PE Ratio | 9.7x |
| Earnings | SEK 31.87m |
| Market Cap | SEK 310.66m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 8.2x |
| PEG Ratio | 0.3x |
Price to Earnings Ratio vs Peers
How does BOULS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.6x | ||
EKF EKF Diagnostics Holdings | 24x | n/a | UK£114.6m |
NIOX NIOX Group | 22.9x | 17.1% | UK£251.5m |
CNSL Cambridge Nutritional Sciences | 44.4x | n/a | UK£7.7m |
SN. Smith & Nephew | 35.3x | 22.5% | UK£8.6b |
BOULS Boule Diagnostics | 9.7x | 33.0% | SEK 310.7m |
Price-To-Earnings vs Peers: BOULS is good value based on its Price-To-Earnings Ratio (9.7x) compared to the peer average (75.6x).
Price to Earnings Ratio vs Industry
How does BOULS's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BOULS is good value based on its Price-To-Earnings Ratio (9.7x) compared to the European Medical Equipment industry average (31.3x).
Price to Earnings Ratio vs Fair Ratio
What is BOULS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 9.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BOULS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arjo
SEK 9.3b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 34.02
7D
0.4%
1Y
-6.6%
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$61.32
7D
4.8%
1Y
-17.1%
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$409.11
7D
2.1%
1Y
-14.2%